Hetero Biopharma launched Darbepoetin alfa in Dhaka, Bangladesh under the brand name ‘Darbesis’.
Hetero Biopharma (HBP) – the biologics arm of Hetero Group in collaboration with Beacon Pharmaceuticals, one of the largest pharmaceutical companies in Bangladesh launched Darbepoetin alfa under the brand name ‘Darbesis’. Under a technology transfer agreement, HBP supported Beacon with technology and had supplied drug substance to launch the product in the country.
The brand ‘Darbesis’ was launched in an event in the presence of 60 nephrologists practicing in Bangladesh. Under Hetero Biopharma’s Knowledge Sharing initiative ‘Knowledge Beyond Barriers’ (KBB), several scientific sessions were organized to emphasize the significance of Darbepoetin alfa in treating CKD.
Dr. Vikranth Reddy, Chief Nephrologist at Care Hospitals, India and one of the Panel doctors for HBP addressed on the paradigm shift of Erythropoietin to Darbepoetin alfa for the treatment of CKD associated Anaemia. Eminent Speakers - Prof Dr. Harun Ur Rashid and Prof. Dr. Muhammad Rafiq Alam - addressed on the ‘Rational Switch of Biosimilar Drugs and Clinical Trials of Darbepoetin Alfa’. The scientific sessions had empowered the doctors in prescribing Darbepoetin alfa to CKD patients.
The event was managed by the entire team of Beacon headed by Mr. Mahmudul Haque Pallab, while the marketing and scientific inputs were supported by Hetero Biopharma team.